AbbVie Inc. (ABBV) Presents Data on Fixed-Duration Venetoclax-Based Combination

On June 12, 2026, AbbVie Inc. (NYSE:ABBV) announced caller Phase 3 information connected a fixed-duration venetoclax-based operation astatine the European Hematology Association 2026 Congress successful Stockholm, Sweden. Final results from the Phase 3 CLL14 proceedings successful antecedently untreated chronic lymphocytic leukemia showed that venetoclax positive obinutuzumab importantly improved progression-free endurance compared with chlorambucil positive obinutuzumab. After a median follow-up of 9.2 years, median progression-free endurance was 6.4 years for venetoclax positive obinutuzumab versus 3.2 years for obinutuzumab positive chlorambucil.

On May 29, 2026, AbbVie Inc. (NYSE:ABBV) announced that the European Commission authorized an expanded statement for Venclyxto to see usage successful operation with acalabrutinib and with ibrutinib for big patients with antecedently untreated chronic lymphocytic leukemia. AbbVie said the all-oral, fixed-duration operation regimens enactment existent standards of attraction and supply further targeted oral medicine options successful the first-line setting, including the imaginable for clip disconnected treatment. The authorization extends to European Union Member States, arsenic good arsenic Iceland, Norway, and Liechtenstein.

On May 27, 2026, AbbVie Inc. (NYSE:ABBV) announced that the FDA approved DECNUPAZ, oregon pivekimab sunirine-pvzy, for big patients with BPDCN, an ultra-rare and assertive hematologic malignancy with constricted attraction options. The support was supported by information from the Phase 1/2 CADENZA trial. In recently diagnosed BPDCN patients, DECNUPAZ showed a composite implicit effect complaint of 69.7% with a median duration of effect of 9.7 months, portion relapsed oregon refractory patients had a composite implicit effect complaint of 15.7% with a median duration of effect of 9.2 months.

AbbVie Inc. (NYSE:ABBV) researches, develops, manufactures, commercializes, and sells medicines and therapies worldwide.

While we admit the imaginable of ABBV arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.